What Is Liraglutide?
Liraglutide is a 97% homologous analogue of native human glucagon-like peptide-1 (GLP-1), engineered for prolonged pharmacological activity. With a molecular weight of approximately 3,751.2 Da and a half-life of roughly 13 hours, liraglutide enabled the first practical once-daily subcutaneous dosing regimen for GLP-1 receptor agonist therapy — a breakthrough that established the clinical proof-of-concept for this entire drug class.
For dosing, reconstitution, and protocol details, see our Liraglutide Dosage Guide: Research Protocol, Reconstitution & Timing (2026).
Developed by Novo Nordisk, liraglutide received FDA approval in January 2010 as Victoza for type 2 diabetes mellitus, making it the first GLP-1 receptor agonist to demonstrate cardiovascular outcome benefits and receive cardiovascular risk reduction labeling. It subsequently received approval as Saxenda in December 2014 for chronic weight management — the first GLP-1 RA approved specifically for obesity treatment.
For researchers, liraglutide remains the historical reference compound for GLP-1 receptor pharmacology. Its well-characterized pharmacokinetic profile, extensive clinical trial record spanning 15+ years, and established safety data make it an invaluable benchmark for evaluating newer GLP-1 receptor agonists including semaglutide and tirzepatide.
---
Molecular Structure and Pharmacological Properties
Structural Design
Liraglutide's molecular architecture explains both its enhanced pharmacological activity and prolonged duration of action compared to native GLP-1:
- •97% sequence homology to native human GLP-1: One amino acid substitution — arginine replacing lysine at position 26 (Arg34Lys26) — prevents the molecule from being a substrate for DPP-4 enzyme cleavage at position 2
- •C16 fatty acid (palmitic acid) attachment via glutamic acid spacer at position 26: This lipid moiety enables reversible albumin binding, dramatically reducing renal clearance and extending half-life from ~2 minutes (native GLP-1) to ~13 hours
- •Once-daily subcutaneous dosing: The 13-hour half-life makes once-daily injection practical while maintaining therapeutic plasma concentrations throughout a 24-hour period
- •Self-association into heptamers: Liraglutide forms self-assembled heptameric structures at the injection site, creating a depot that further extends absorption
These structural innovations — developed in the early 2000s — established the pharmacological engineering principles later refined in semaglutide (weekly dosing) and tirzepatide.
Pharmacokinetic Profile
| Parameter | Value |
|---|---|
| Molecular weight | 3,751.2 Da |
| Half-life | ~13 hours |
| Peak plasma concentration (Tmax) | 8–12 hours post-injection |
| Absolute bioavailability | ~55% (subcutaneous) |
| Primary elimination | Proteolytic degradation (urinary/fecal) |
| Protein binding | >98% (albumin) |
| Steady state | Achieved at 3–5 days with once-daily dosing |
| CAS Number | 204656-20-2 |
| Molecular formula | C₁₇₂H₂₆₅N₄₃O₅₁ |
---
Mechanism of Action
GLP-1 Receptor Binding and Signal Transduction
Liraglutide exerts its biological effects by binding to and activating the glucagon-like peptide-1 receptor (GLP-1R), a class B G protein-coupled receptor (GPCR) expressed throughout the body, particularly in:
- •Pancreatic beta cells: Primary site of insulin secretion stimulation
- •Pancreatic alpha cells: Site of glucagon suppression
- •Gastric parietal cells and enteric nervous system: Mediating gastric emptying delay
- •Hypothalamus, brainstem (area postrema/NTS): Central appetite regulation
- •Cardiac myocytes and coronary vasculature: Contributing to cardioprotective effects
- •Hepatocytes: Direct effects on hepatic lipid metabolism
- •Peripheral sensory and vagal afferent neurons: Modulating satiety signals
Upon GLP-1R binding, liraglutide activates the Gs protein pathway, increasing intracellular cAMP. This triggers PKA (protein kinase A) and Epac2 (exchange protein activated by cAMP 2), with downstream effects on insulin vesicle exocytosis, potassium channel closure (KATP), and calcium channel activation.
Glucose-Dependent Insulin Secretion
A critical safety feature of liraglutide (and all GLP-1 RAs) is that its insulinotropic action is strictly glucose-dependent. Below a glucose threshold of approximately 70 mg/dL, GLP-1R signaling does not appreciably stimulate insulin release, effectively eliminating risk of hypoglycemia in monotherapy.
At elevated glucose concentrations, however, liraglutide amplifies insulin secretion through:
1. Direct beta-cell stimulation via cAMP/PKA pathway
2. Enhanced glucose sensing through glucokinase upregulation
3. Increased transcription of proinsulin and insulin genes
4. Promotion of beta-cell proliferation and inhibition of apoptosis (demonstrated in rodent models and in vitro human islet preparations)
Glucagon Suppression and Hepatic Effects
GLP-1 receptors on pancreatic alpha cells mediate glucose-dependent glucagon suppression. This reduces hepatic glucose output (HGO) — a key driver of fasting hyperglycemia in T2DM. Liraglutide reduces postprandial glucagon excursions by 20–30% in clinical studies, contributing substantially to overall glycemic control.
Gastric Emptying Delay
By activating GLP-1 receptors in the gastric wall and enteric nervous system, liraglutide slows the rate of gastric emptying. This:
- •Blunts postprandial glucose spikes by spreading carbohydrate absorption over a longer period
- •Contributes to early satiety by distending the stomach for longer periods
- •Is dose-dependent and attenuates with chronic treatment (tachyphylaxis after 4–8 weeks)
Central Appetite Regulation
Liraglutide crosses the blood-brain barrier at circumventricular organs (primarily area postrema) and activates GLP-1 receptors in the hypothalamic arcuate nucleus and nucleus tractus solitarius. This:
- •Reduces expression of orexigenic (appetite-stimulating) neuropeptides: NPY (neuropeptide Y), AgRP (agouti-related protein)
- •Increases expression of anorexigenic (appetite-suppressing) signals: α-MSH (via POMC/CART pathway)
- •Activates vagal afferent neurons, communicating satiety from gut to brain
- •Reduces reward-driven food intake via actions on dopaminergic pathways in the ventral tegmental area
---
Clinical Trial Evidence: Glycemic Control
LEAD Program (Liraglutide Effect and Action in Diabetes)
The LEAD clinical program (LEAD 1–6) established liraglutide's glycemic efficacy across a spectrum of T2DM disease stages and treatment combinations.
#### LEAD-1: Add-On to Sulfonylurea
Design: 26-week, double-blind trial; liraglutide (1.2mg or 1.8mg) added to glimepiride vs placebo + glimepiride (N=1,041)
Results (liraglutide 1.8mg vs placebo):
- •HbA1c: −1.08% vs +0.23%
- •Body weight: −0.2 kg vs +0.1 kg
- •Proportion at HbA1c <7%: 42% vs 8%
#### LEAD-2: Add-On to Metformin
Design: 26-week active-controlled trial; liraglutide vs glimepiride, both on metformin background (N=1,091)
Results (liraglutide 1.8mg vs glimepiride):
- •HbA1c reduction: −1.0% vs −1.0% (non-inferior)
- •Body weight: −2.8 kg vs +1.0 kg (significant advantage vs sulfonylurea)
- •Hypoglycemia: 3-fold lower with liraglutide vs glimepiride
#### LEAD-3: Monotherapy
Design: 52-week monotherapy trial; liraglutide vs glimepiride in T2DM (N=745)
Results (liraglutide 1.8mg vs glimepiride):
- •HbA1c: −1.14% vs −0.84% (significantly superior)
- •Weight: −2.45 kg vs +1.12 kg
- •Maintained superiority over 52 weeks
#### LEAD-6: Head-to-Head vs Exenatide Twice Daily
Design: 26-week open-label comparative trial; liraglutide 1.8mg vs exenatide 10μg BID (N=464)
Results (liraglutide vs exenatide BID):
- •HbA1c: −1.12% vs −0.79% (significantly superior)
- •Weight: −3.24 kg vs −2.87 kg (comparable)
- •Nausea: 25.5% vs 28.0% (comparable GI tolerability)
---
Clinical Trial Evidence: Cardiovascular Outcomes
LEADER Trial — Landmark Cardiovascular Outcomes
The LEADER trial (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) is perhaps the most important clinical trial in GLP-1 RA history. It was the first randomized controlled trial to demonstrate that a GLP-1 receptor agonist reduces major adverse cardiovascular events (MACE) in high-risk patients.
Design: Double-blind, placebo-controlled cardiovascular outcomes trial; liraglutide 1.8mg vs placebo in T2DM patients with established CV disease or high CV risk (N=9,340); median follow-up 3.8 years
Primary Endpoint (3-point MACE: CV death, non-fatal MI, non-fatal stroke):
- •Liraglutide: 13.0% vs Placebo: 14.9% (HR 0.87, 95% CI 0.78–0.97, p=0.01)
- •13% relative risk reduction in MACE
- •Number needed to treat (NNT) ≈ 66 over 3.8 years
Key Secondary Endpoints:
| Outcome | Liraglutide | Placebo | HR (95% CI) |
|---|---|---|---|
| CV death | 4.7% | 6.0% | 0.78 (0.66–0.93) |
| All-cause mortality | 8.2% | 9.6% | 0.85 (0.74–0.97) |
| Fatal/non-fatal MI | 6.8% | 7.6% | 0.88 (0.75–1.03) |
| Fatal/non-fatal stroke | 3.4% | 3.8% | 0.89 (0.72–1.11) |
| Heart failure hospitalization | 4.7% | 5.3% | 0.87 (0.73–1.05) |
| Nephropathy (new/worsening) | 5.7% | 7.2% | 0.78 (0.67–0.92) |
Critical insight: The cardiovascular mortality benefit emerged after approximately 12 months of treatment, suggesting the benefit arises from a direct cardioprotective mechanism (anti-inflammatory, anti-atherosclerotic, renoprotective) rather than purely from glycemic or weight improvement.
This trial led to liraglutide receiving FDA label update in 2017 for cardiovascular risk reduction in T2DM — the first such labeling for any antidiabetic agent.
Reference: Marso SP, et al. N Engl J Med 2016;375(4):311–322 (LEADER) PMID: 27295427
---
Clinical Trial Evidence: Weight Management (SCALE Program)
SCALE Obesity and Prediabetes Trial
Design: 56-week + 12-week follow-off extension; liraglutide 3.0mg vs placebo, with diet/exercise intervention, in adults with obesity or overweight with comorbidities (N=3,731)
Results (liraglutide 3.0mg vs placebo):
| Endpoint | Liraglutide 3.0mg | Placebo |
|---|---|---|
| Mean weight loss | −8.4 kg (−8.0%) | −2.8 kg (−2.6%) |
| ≥5% weight loss | 63.2% | 27.1% |
| ≥10% weight loss | 33.1% | 10.6% |
| ≥15% weight loss | 14.4% | 3.5% |
Prediabetes subgroup at 160 weeks: 26% of liraglutide-treated subjects vs 40% of placebo developed T2DM — a 36% relative risk reduction for diabetes conversion.
Reference: Pi-Sunyer X, et al. N Engl J Med 2015;373(1):11–22 (SCALE) PMID: 26132939
SCALE Maintenance Trial
Design: 56-week trial following 4–12 weeks of low-calorie diet run-in; liraglutide 3.0mg vs placebo for weight maintenance (N=422)
Results: Liraglutide maintained weight loss from run-in phase (additional −6.2% vs −0.2% for placebo from run-in endpoint), demonstrating that pharmacotherapy sustains weight loss that would otherwise be regained.
SCALE Diabetes Trial
Design: 56-week trial in T2DM patients with obesity; liraglutide 1.2mg / 3.0mg vs placebo (N=846)
Results (liraglutide 3.0mg vs placebo):
- •Weight loss: −5.9% vs −2.0%
- •HbA1c: −1.33% vs −0.38%
- •≥5% weight loss: 54.3% vs 21.4%
---
Clinical Trial Evidence: Non-Alcoholic Fatty Liver Disease
LIRA-NAFLD Trial
Design: 48-week randomized trial; liraglutide 1.8mg vs placebo in patients with biopsy-proven NASH (N=52)
Results:
- •Resolution of NASH (on biopsy): 39% liraglutide vs 9% placebo (p=0.019)
- •Progression to cirrhosis: 9% vs 36% (lower with liraglutide)
- •Weight loss: −5.3% vs −0.5%
- •Liver fat (MRI): −32% vs −2%
This was one of the first trials to demonstrate histological improvement in NASH with a GLP-1 RA, establishing the hepatic benefits that subsequent GLP-1 RA research (including tirzepatide SYNERGY-NASH) has since expanded upon.
---
FDA Approval History
Victoza (T2DM Indication)
- •Approval date: January 25, 2010
- •Indication: Adjunct to diet and exercise to improve glycemic control in adults with T2DM
- •Approved doses: 1.2mg or 1.8mg subcutaneous injection once daily
- •Historical significance: Second GLP-1 RA approved (after exenatide twice-daily in 2005), and first with once-daily dosing
- •CV labeling update (2017): Added cardiovascular risk reduction indication following LEADER trial data — the first antidiabetic agent to receive this labeling based on outcomes trial data
Saxenda (Obesity/Weight Management)
- •Approval date: December 23, 2014
- •Indication: Chronic weight management in adults with BMI ≥30 kg/m², or ≥27 kg/m² with ≥1 weight-related comorbidity, in conjunction with diet and exercise
- •Approved dose: 3.0mg once daily (titrated from 0.6mg over 5 weeks)
- •Historical significance: First GLP-1 RA approved for obesity treatment; paved the way for semaglutide 2.4mg (Wegovy, 2021) and tirzepatide 15mg (Zepbound, 2023)
- •Pediatric approval (2020): Extended to adolescents aged 12–17 with initial BMI at or above the 95th percentile for age and sex
---
Safety and Adverse Event Profile
Gastrointestinal Effects
The most common adverse events with liraglutide are GI-related, consistent with GLP-1R agonism:
From SCALE Obesity and Prediabetes trial (Saxenda 3.0mg):
- •Nausea: 32.1% vs 8.5% (placebo) — most common AE
- •Diarrhea: 17.5% vs 8.3%
- •Constipation: 19.3% vs 8.5%
- •Vomiting: 11.0% vs 3.3%
- •Dyspepsia: 9.3% vs 3.4%
Timing: GI events peak during dose escalation (first 5 weeks) and substantially diminish with chronic treatment. Approximately 9.9% of Saxenda patients discontinued due to GI adverse events vs 0.7% on placebo.
Management strategy: Slow dose escalation protocol (0.6mg → 1.2mg → 1.8mg → 2.4mg → 3.0mg, each step at 1-week intervals), eating smaller portions, avoiding high-fat meals.
Hypoglycemia Risk
- •In non-T2DM subjects (SCALE program): Symptomatic hypoglycemia occurs in ~1.5% vs ~0.9% (placebo), very low risk
- •In T2DM: Risk increased when combined with insulin secretagogues (sulfonylureas) or exogenous insulin; requires dose reduction of these agents
- •Severe hypoglycemia in monotherapy: extremely rare (glucose-dependent mechanism)
Immunogenicity
Liraglutide immunogenicity data from LEADER (N=9,340):
- •Anti-liraglutide antibodies detected in approximately 9% of patients
- •Antibody formation did not affect glycemic efficacy or safety in the majority of cases
- •Small subset (~5% of antibody-positive patients) showed reduced efficacy
- •Cross-reactivity with native GLP-1: low; cross-reactivity with other GLP-1 RAs: low
Heart Rate Increase
- •Mean heart rate increase: +2 to +3 bpm at therapeutic doses
- •Class effect of GLP-1 receptor agonists
- •Mechanism: GLP-1R-mediated sinoatrial node stimulation
- •Clinical significance: generally modest; monitor in patients with known arrhythmias or tachycardia
Pancreatitis
- •Acute pancreatitis: rare; reported in LEADER at similar rates in liraglutide vs placebo (0.4% vs 0.5%)
- •FDA issued labeling precaution for all GLP-1 RAs regarding pancreatitis
- •Discontinue immediately if pancreatitis suspected
- •Caution in patients with prior history of pancreatitis
Gallbladder and Biliary Disease
- •Cholelithiasis: incidence ~2.1% (liraglutide 1.8mg) vs ~1.3% (placebo) in LEADER
- •Rapid weight loss with higher doses (Saxenda) increases gallstone risk
- •Monitor for biliary symptoms during treatment
Thyroid
- •Black box warning: Thyroid C-cell tumors in rodent studies at clinically relevant exposures
- •C-cell tumors: Dose- and duration-dependent in mice and rats; mechanism involves GLP-1R activation on C-cells (which humans express at much lower levels)
- •Human epidemiological data (15+ years): No confirmed causal link to medullary thyroid carcinoma (MTC)
- •Contraindication: Personal or family history of MTC or Multiple Endocrine Neoplasia type 2 (MEN2)
- •Recommendation: Routine calcitonin monitoring not required but may be considered
Renal Effects
From LEADER trial renal substudy:
- •New or worsening nephropathy: 5.7% vs 7.2% (HR 0.78, 95% CI 0.67–0.92)
- •Primarily driven by reduction in macroalbuminuria
- •eGFR: small decline at initiation (hemodynamic effect of reduced glucosuria), stabilizes over time
- •Caution in severe renal impairment (CrCl <30 mL/min) — dose adjustment may be needed
Contraindications
1. Personal or family history of medullary thyroid carcinoma
2. Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
3. Prior serious hypersensitivity to liraglutide
---
Dosing Research Protocols
Important disclaimer: The following dosing information is published from clinical trial protocols for educational reference only. Liraglutide is a prescription medication requiring physician oversight.
T2DM Protocol (Victoza)
| Week | Dose |
|---|---|
| 1–4+ | 0.6 mg/day (initiation dose, not effective for glycemia) |
| 5+ | 1.2 mg/day (glycemically effective, most patients) |
| If insufficient response | 1.8 mg/day |
Administration: Once daily, any time, with or without food. Subcutaneous injection into abdomen, thigh, or upper arm. Rotate injection sites.
Weight Management Protocol (Saxenda)
| Week | Dose |
|---|---|
| Week 1 | 0.6 mg/day |
| Week 2 | 1.2 mg/day |
| Week 3 | 1.8 mg/day |
| Week 4 | 2.4 mg/day |
| Week 5+ | 3.0 mg/day |
Response assessment at 16 weeks: If patient has not lost ≥4% of initial body weight, discontinue — unlikely to achieve meaningful weight loss with continued treatment.
Research Storage and Handling
| Specification | Detail |
|---|---|
| Molecular weight | 3,751.2 Da |
| CAS Number | 204656-20-2 |
| Appearance | Clear, colorless solution (pre-formulated) or white lyophilized powder |
| Storage | 2–8°C (refrigerated); do not freeze |
| In-use storage | Room temperature (up to 30°C) for up to 30 days |
| Purity standard | ≥98% by HPLC (research preparations) |
| Classification | Research Use Only (RUO) |
---
Comparison to Semaglutide and Tirzepatide
Liraglutide was the benchmark against which semaglutide and tirzepatide were developed and tested. Key comparative insights:
| Parameter | Liraglutide | Semaglutide 1mg | Tirzepatide 15mg |
|---|---|---|---|
| Dosing frequency | Once daily | Once weekly | Once weekly |
| Max HbA1c reduction | ~1.1% | ~1.5% | ~2.4% |
| Max weight loss (obesity trial) | ~8.0% | ~14.9% | ~20.9% |
| MACE reduction | 13% (LEADER) | 26% (SUSTAIN-6) | Pending (SURPASS-CVOT) |
| GI tolerability | Moderate | Moderate | Better than semaglutide |
| Mechanism | GLP-1R agonist | GLP-1R agonist | GLP-1R + GIPR dual agonist |
| Half-life | ~13 hours | ~7 days | ~5 days |
Semaglutide's once-weekly dosing (achieved via fatty acid chain extension enabling stronger albumin binding) largely supplanted liraglutide's once-daily protocol in clinical practice. However, liraglutide's 15+ years of real-world safety data, its established NAFLD/NASH benefits, and its specific adolescent weight management approval maintain its research and clinical relevance.
For an in-depth comparison of all GLP-1 receptor agonists, see our GLP-1 Receptor Agonists Complete Research Overview.
---
Emerging and Ongoing Research
NASH/MASH
The LIRA-NAFLD data prompted extensive research into GLP-1 RA effects on liver disease. Larger trials using semaglutide (NASH) and tirzepatide (SYNERGY-NASH) have since confirmed and extended liraglutide's findings, validating the GLP-1 RA class as promising MASH therapies.
Alzheimer's Disease
The ELAD trial (Evaluation of Liraglutide in Alzheimer's Disease) evaluated liraglutide in patients with mild Alzheimer's, based on preclinical data showing GLP-1 receptor expression in the brain and neuroprotective effects in animal models. Results were mixed; however, this work stimulated broader investigation of GLP-1 RAs as potential neuroprotective agents.
Polycystic Kidney Disease
Preclinical data suggest GLP-1R activation may slow cystic growth in polycystic kidney disease (PKD); liraglutide is being studied in early human trials.
Pediatric Obesity
Saxenda's 2020 approval for adolescents (12–17) with obesity (BMI ≥95th percentile) was supported by the SCALE Adolescents trial, demonstrating significant weight reduction vs placebo. Liraglutide remains the only GLP-1 RA FDA-approved in this adolescent age group with semaglutide's Wegovy receiving pediatric approval in 2023 for ages 12+.
---
Tools for Researchers
- •Peptide Dose Calculator: Calculate research volumes and dose-volume calculations
- •Dose Plotter: Visualize once-daily escalation protocols
- •Compare Liraglutide Suppliers: Side-by-side price and purity comparison across verified suppliers
- •GLP-1 Receptor Agonists Complete Research Overview: Comprehensive cross-compound analysis
- •Semaglutide vs Tirzepatide Comparison: Next-generation compound comparison
---
Key Research References
1. Marso SP, et al. "Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes." N Engl J Med. 2016;375(4):311–322. [LEADER] PMID: 27295427
2. Pi-Sunyer X, et al. "A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management." N Engl J Med. 2015;373(1):11–22. [SCALE] PMID: 26132939
4. Buse JB, et al. "Liraglutide once a day versus exenatide twice a day for type 2 diabetes." Lancet. 2009;374(9683):39–47. [LEAD-6] PMID: 19515413
6. Marre M, et al. "Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks." Diabet Med. 2009;26(3):268–278. [LEAD-1] PMID: 19317822
7. Nauck M, et al. "Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin." Diabetes Care. 2009;32(1):84–90. [LEAD-2] PMID: 18931095
---
Research Disclaimer
The content on this page is intended for educational and informational purposes for the scientific research community only. Liraglutide (Victoza®, Saxenda®) is a prescription medication approved by the FDA for specific indications and is not approved for self-administration or use outside of medical supervision.
All clinical data referenced is derived from published, peer-reviewed research. Peptides.SO does not provide medical advice, diagnose conditions, or recommend treatments. Researchers and consumers should consult qualified healthcare professionals for all medical decisions.
Peptide compounds sold through verified suppliers on Peptides.SO are sold for laboratory research use only (RUO) and are not intended for human consumption, therapeutic use, or veterinary administration.
---
Further Reading:
- •Retatrutide (LY3437943): Triple Hormone Receptor Agonist — Complete Research Profile
- •Semaglutide Research Guide 2026: Mechanism, Dosing, Sources, and Pricing
- •5-Amino-1MQ: NNMT Inhibitor for Metabolic and Obesity Research
- •Glucagon: The Counterregulatory Pancreatic Peptide in Metabolic, Hepatic, and Multi-Receptor Research (2026)
- •Peptide Stack Builder
- •Dosage Chart
Live Research Peptide Pricing Snapshot: Liraglutide (2026)
Live data from Peptides.SO's supplier database across 4 active suppliers and 5 in-stock liraglutide offers (August 2026):
| Supplier | Vial Size | Price | Price/mg |
|---|---|---|---|
| Peptides World | 5 mg | $99.00 | $19.80/mg |
| Genesis Peptides | 1 mg | $40.00 | $40.00/mg |
| Iron Mountain Labz | 1 mg | $45.80 | $45.80/mg |
| Genetic Peptide | 1 mg | $150.00 | $150.00/mg |
| Iron Mountain Labz | 1 mg (large) | $304.64 | $304.64/mg |
Data sourced from Peptides.SO live listings, August 2026. Prices subject to change. Research Use Only (RUO).
Liraglutide has a smaller active supplier pool than newer-generation GLP-1/GIP agonists like semaglutide and tirzepatide, reflecting reduced research demand as longer-acting once-weekly analogs have become the dominant research focus. The 5 mg multi-dose format from Peptides World offers the best per-mg value for extended protocols. Live comparison: Liraglutide price listing.
Frequently Asked Questions
Is liraglutide FDA-approved?
Yes — liraglutide is FDA-approved as Victoza for type 2 diabetes and Saxenda for chronic weight management, and served as a mechanistic foundation for later once-weekly GLP-1 receptor agonists (Molecular Metabolism review, PMID 33068776).
How does liraglutide produce weight-loss effects in research models?
Preclinical research localized liraglutide's weight-reducing effect to direct action on GLP-1 receptors in the arcuate nucleus of the hypothalamus, independent of vagal afferent signaling (Journal of Clinical Investigation, PMID 25202980).
Why does liraglutide require daily dosing while semaglutide and tirzepatide are weekly?
Liraglutide has a shorter half-life (~13 hours) due to less extensive fatty-acid-mediated albumin binding compared to the later-generation analogs, a pharmacokinetic distinction covered further in the Comparison to Semaglutide and Tirzepatide section above.
What broader GLP-1 physiology research context applies to liraglutide?
Liraglutide research sits within the larger GLP-1 receptor agonist pharmacology literature spanning glycemic, weight, and cardiometabolic research domains (Molecular Metabolism, PMID 34626851).
Why is the liraglutide supplier pool smaller than semaglutide's?
Research market demand has increasingly shifted toward once-weekly analogs (semaglutide, tirzepatide) that require fewer research-protocol administrations, reducing the relative commercial incentive for liraglutide-specific supplier listings.
Where can I check current liraglutide supplier pricing?
Live pricing across all tracked suppliers is available on the Liraglutide listing page.
2026 Research Update
Liraglutide research in 2025–2026 has been partly overshadowed by next-generation GLP-1 and dual-agonist compounds (semaglutide, tirzepatide, retatrutide), but new research continues to clarify liraglutide's unique pharmacological profile. A 2025 meta-analysis in Cardiovascular Diabetology confirmed liraglutide's MACE reduction benefit in patients with established cardiovascular disease (drawn from LEADER trial follow-up data), with a hazard ratio of 0.87 — a clinically meaningful effect size that remains relevant in risk-stratified prescribing decisions.
Research interest has also grown in liraglutide's neuroprotective properties. Pre-clinical data published in 2025 demonstrated that GLP-1R activation by liraglutide reduces tau phosphorylation and amyloid burden in murine Alzheimer's models. Human trials examining liraglutide in mild cognitive impairment are ongoing as of 2026, with the Novo Nordisk-sponsored ELAD trial among those most closely watched.
Frequently Asked Questions
What is liraglutide and what is it approved for?
Liraglutide is a GLP-1 receptor agonist — a synthetic analog of human glucagon-like peptide-1 — that activates GLP-1 receptors to stimulate insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite. It is FDA approved under two brand names: Victoza (1.2 mg/1.8 mg, for type 2 diabetes management) and Saxenda (3.0 mg, for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity). It has been on the market since 2010, making it one of the most clinically studied GLP-1 agonists available.
How does liraglutide differ from semaglutide?
Both are GLP-1 receptor agonists developed by Novo Nordisk, but they differ in duration of action and potency. Liraglutide has a half-life of approximately 13 hours, requiring once-daily injection. Semaglutide has a half-life of approximately 7 days (weekly dosing). In clinical trials, semaglutide (especially the 2.4 mg Wegovy dose) produces greater average weight loss (15-17%) compared to liraglutide Saxenda (~5-8%). Semaglutide is now generally preferred for weight management, while liraglutide retains a role where its shorter half-life is clinically advantageous.
Is liraglutide available in pill form?
No. Liraglutide is only available as a subcutaneous injection. GLP-1 peptides are degraded by gastrointestinal peptidases when taken orally; this is why oral semaglutide (Rybelsus) required special absorption-enhancing formulation (SNAC), and liraglutide has not undergone equivalent development. Research-grade liraglutide for laboratory use is also supplied in injectable form.
What does the LEADER trial tell us about liraglutide?
The LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) trial was a landmark Phase 3 cardiovascular outcomes trial in 9,340 patients with type 2 diabetes and high cardiovascular risk. It demonstrated that liraglutide 1.8 mg reduced the primary MACE endpoint (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) by 13% relative to placebo over a median follow-up of 3.8 years. This established liraglutide as the first GLP-1 agonist with demonstrated cardiovascular risk reduction — a finding since replicated with semaglutide in SUSTAIN-6.
What is liraglutide's mechanism for weight loss?
Liraglutide reduces weight primarily through three mechanisms: (1) centrally, by activating GLP-1 receptors in the hypothalamus and brainstem to reduce appetite and food-seeking behavior; (2) peripherally, by slowing gastric emptying, which prolongs satiety; and (3) by reducing glucagon secretion, which affects hepatic glucose output and indirectly reduces caloric cycling. Unlike some weight-loss drugs, liraglutide does not suppress dopamine or have direct sympathomimetic activity.
Can liraglutide be used in research to study GLP-1 receptor biology?
Yes. Research-grade liraglutide is commonly used in pre-clinical GLP-1 receptor biology studies. Its well-characterized pharmacokinetics, high GLP-1R selectivity (unlike tirzepatide, which is dual GIP/GLP-1), and long preclinical and clinical dataset make it a useful reference compound in metabolic research. It is also used in neurodegeneration research as a tool to study GLP-1R signaling in brain tissue.
> Disclaimer: This article covers liraglutide as both an FDA-approved medication and a research compound. FDA-approved liraglutide (Victoza/Saxenda) is a prescription drug — seek licensed medical advice before use. Research-grade liraglutide is for laboratory and pre-clinical use only.